Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JTO.0b013e31827450ae | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Korea University, Sejong, Sejong, Korea, Republic of (South).
Background: Amyloid-β accumulation is a pivotal factor in Alzheimer's disease (AD) progression. As treatment for AD has not been successful yet, the most effective approach lies in early diagnosis and the subsequent delay of disease progression. Hence, this study introduces a deep learning model to predict amyloid-β accumulation in the brain.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Washington University School of Medicine, St. Louis, MO, USA.
Background: P-tau217 has emerged as a compelling alternative to long-established p-tau181 to accurately measure tau modifications in biofluids in response to brain Abeta and tau deposition in Alzheimer's disease (AD). Understanding the specificity and significance of p-tau217 changes over AD stages is critical to interpret its potential response to treatments against Abeta and tau aggregation.
Methods: We measured p-tau217 phosphorylation by mass spectrometry.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Background: Synaptic loss, a key indicator of cognitive decline in neurodegenerative diseases, lacks a clinical biomarker, but emerging PET-scan tracers targeting synaptic vesicle protein 2A (SV2A) show promise. The current understanding of regional changes in neurodegenerative disorders and the distribution of SV2A in the human brain is quite limited. This knowledge gap presents challenges when assessing the feasibility of using SV2A tracers in therapeutic applications.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Paris Brain Institute, PARIS, France.
Background: Over-representation of several health conditions (such as diabetes, hearing loss, etc) have been identified up to 15 years before Alzheimer's Disease (AD) diagnosis through the study of electronic health records [1]. Mechanisms underlying these associations remain elusive. We propose to study the associations between these co-pathologies (proxied by genetic risk scores), and the physiological and clinical evolution of AD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!